SMARTSTREAM-TECHNOLOGIES
12.10.2021 09:02:08 CEST | Business Wire | Press release
SmartStream Technologies, the financial Transaction Lifecycle Management (TLM® ) solutions provider, today announces that Fisher & Paykel Appliances, the global manufacturer of household appliances, operating in over 50 countries, has signed with SmartStream Air - providing the firm’s finance team with cloud-native, AI technology for bank reconciliations.
As a leading appliance manufacturer headquartered in New Zealand, Fisher & Paykel Appliances approached SmartStream to evaluate their data management and reconciliations tooling. SmartStream Air is agnostic to structured data formats requiring zero IT skillset to use, and will automate the finance division’s data reconciliation processing, at speed. The AI solution will easily integrate with Fisher & Paykel Appliances’ existing systems enabling them to perform additional analytics on reconciled data. In addition, it will provide business intelligence by connecting to third-party tools already deployed in-house.
SmartStream Air’s software as a service (SaaS) ease of deployment in numerous locations was a key deciding factor as Fisher & Paykel Appliances will look to roll out the product in New Zealand, followed by multiple locations in Asia Pacific and then globally. The company was looking to automate and enhance their currently manual reconciliation operating model to support their growing business volumes globally.
The process to proof-of-concept for SmartStream Air was quick in comparison to the three other competitor reconciliation solutions that were under consideration. As a self-service, AI enabled, cloud-native application, agnostic to structured data formats and data reconciliation types, with little configuration to setup, the go-live was immediate with higher levels of productivity to meet the growing business at Fisher & Paykel.
Nicole Adamson, Senior Corporate Controller, Fisher & Paykel, states: “We are pleased to partner with SmartStream, it is in our interest to keep up with the latest technologies and always improve our internal processes and productivity. We needed to move away from the manual operations to an automated data reconciliation model, which eliminates operational risk, whilst being able to scale volumes more cost-effectively. We felt SmartStream Air was the right choice to help us achieve this objective”.
Victoria Harverson, Global Head of Business Development for SmartStream Air, comments: “We are delighted to have Fisher and Paykel as a SmartStream Air customer. This partnership is significant as it recognises our deepening footprint in New Zealand, whilst also establishing a new relationship with a customer in the manufacturing sector. SmartStream Air is perfect for this type of operating model and really showcases how easy and cost-effective it can be for a company finance team to quickly control risk and see real tangible ROI by leveraging the latest self-service AI tooling”.
With SmartStream Air users can use the power of AI to autonomously build and learn data matching behaviour, transforming typical data reconciliation tasks – reducing the time it takes to just seconds. Speed of go-to-market and scalability was also a winning factor as SmartStream Air has been designed to be live the same day and is built for performance when it comes to high-volume processing.
Ends
About Fisher & Paykel
Fisher & Paykel Appliances has been designing products since 1934 and has grown into a global company with products sold in more than 50 countries around the world.
Our design heritage is founded on a pioneering spirit and a culture of curiosity. We’ve built our legacy with a future focus that still stays true to the fundamentals of sustainable design. We believe technology should always begin with the people who use it. This has seen us challenge conventional appliance design to create products that deliver to genuine human need.
Our ongoing research and development is backed by a culture of open innovation, collaboration and curiosity – one that seeks to uncover insights and ideas that connect with our customers and respect our planet.
About SmartStream
View source version on businesswire.com: https://www.businesswire.com/news/home/20211012005110/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release
Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release
Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom